Rx Patent Litigation Relates Mostly To Formulation, Use Patents, FTC Says

A majority of drug patent challenges involve patents that do not cover the active ingredient, Federal Trade Commission Chairman Timothy Muris told a Senate Commerce Committee hearing on generic drugs April 23